Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22929119 | 0.75 | NAALAD2 (0.32) | NAALAD2 | |
| SCHEMBL17323630 | 0.72 | FOLH1 (0.47) | NAALAD2 | |
| SCHEMBL16213761 | 0.70 | CYP1A2 (0.50) | NAALAD2 | |
| SCHEMBL17874640 | 0.70 | ACE (0.36) | — | |
| SCHEMBL10942770 | 0.69 | ALDH1A1 (0.43) | — | |
| SCHEMBL24899880 | 0.69 | CA1 (0.38) | — | |
| SCHEMBL15381923 | 0.68 | CYP1A2 (0.47) | NAALAD2 | |
| SCHEMBL16213765 | 0.68 | TSHR (0.40) | NAALAD2 | |
| SCHEMBL16644774 | 0.67 | ALDH1A1 (0.36) | — | |
| SCHEMBL17656893 | 0.67 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10905766-B2 | Therapeutic compositions and methods for treatment of muscle wasting diseases | OREGON STATE UNIVERSITY (US) | 2021-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905766-B2 | Therapeutic compositions and methods for treatment of muscle wasting diseases | TNNC1, PYGM, MYLK2 | NAALAD2 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.